Literature DB >> 30633430

Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study.

Dea Siggaard Stenbaek1,2,3, Sara Kristiansen1,2,3, Daniel Burmester1,2,3, Martin Korsbak Madsen1,2,3, Vibe Gedsoe Frokjaer1,2,3, Gitte Moos Knudsen1,2,3, Patrick MacDonald Fisher1,2,3.   

Abstract

Recent research found lasting increases in personality trait Openness in healthy individuals and patients after administration of the serotonin 2A receptor (5-HT2A R) agonist psilocybin. However, no studies have investigated whether 5-HT2A R availability as imaged using positron emission tomography (PET) is associated with this trait. In 159 healthy individuals (53 females), the association between 5-HT2A R binding in neocortex imaged with [18 F]altanserin or [11 C]Cimbi-36 PET and personality trait Openness was investigated using linear regression models. In these models the influence of sex on the association was also investigated. Trait Openness was assessed with the NEO Personality Inventory-Revised. No significant associations between neocortical 5-HT2A R binding and trait Openness were found for [18 F]altanserin (p = 0.5) or [11 C]Cimbi-36 (p = 0.8). Pooling the data in a combined model did not substantially change our results (p = 0.4). No significant interactions with sex were found (p > 0.35). Our results indicate that differences in 5-HT2A R availability are not related to variations in trait Openness in healthy individuals. Although stimulation of the 5-HT2A R with compounds such as psilocybin may contribute to long-term changes in trait Openness, there is no evidence in favor of an association between 5-HT2A R and trait Openness.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  5-HT2A; NEO personality inventory; PET scan; [11C]Cimbi-36; [18F]altanserin; biomarkers; personality; serotonin; trait Openness

Mesh:

Substances:

Year:  2019        PMID: 30633430      PMCID: PMC6865516          DOI: 10.1002/hbm.24511

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  57 in total

1.  Temperament, character and serotonin activity in the human brain: a positron emission tomography study based on a general population cohort.

Authors:  L Tuominen; J Salo; J Hirvonen; K Någren; P Laine; T Melartin; E Isometsä; J Viikari; C R Cloninger; O Raitakari; J Hietala; L Keltikangas-Järvinen
Journal:  Psychol Med       Date:  2012-07-31       Impact factor: 7.723

2.  Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Authors:  Roland R Griffiths; Matthew W Johnson; William A Richards; Brian D Richards; Una McCann; Robert Jesse
Journal:  Psychopharmacology (Berl)       Date:  2011-06-15       Impact factor: 4.530

3.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

Authors:  Charles S Grob; Alicia L Danforth; Gurpreet S Chopra; Marycie Hagerty; Charles R McKay; Adam L Halberstadt; George R Greer
Journal:  Arch Gen Psychiatry       Date:  2010-09-06

4.  Serotonin 2A receptor agonist binding in the human brain with [(11)C]Cimbi-36: Test-retest reproducibility and head-to-head comparison with the antagonist [(18)F]altanserin.

Authors:  Anders Ettrup; Claus Svarer; Brenda McMahon; Sofi da Cunha-Bang; Szabolcs Lehel; Kirsten Møller; Agnete Dyssegaard; Melanie Ganz; Vincent Beliveau; Louise Møller Jørgensen; Nic Gillings; Gitte Moos Knudsen
Journal:  Neuroimage       Date:  2016-02-11       Impact factor: 6.556

5.  A nonlinear relationship between cerebral serotonin transporter and 5-HT(2A) receptor binding: an in vivo molecular imaging study in humans.

Authors:  David Erritzoe; Klaus Holst; Vibe G Frokjaer; Cecilie L Licht; Jan Kalbitzer; Finn A Nielsen; Claus Svarer; Jacob Madsen; Gitte Knudsen
Journal:  J Neurosci       Date:  2010-03-03       Impact factor: 6.167

6.  Age, sex, and reproductive hormone effects on brain serotonin-1A and serotonin-2A receptor binding in a healthy population.

Authors:  Eydie L Moses-Kolko; Julie C Price; Nilesh Shah; Sarah Berga; Susan M Sereika; Patrick M Fisher; Rhaven Coleman; Carl Becker; N Scott Mason; Tammy Loucks; Carolyn C Meltzer
Journal:  Neuropsychopharmacology       Date:  2011-08-17       Impact factor: 7.853

7.  Openness to Experience and Intellect Differentially Predict Creative Achievement in the Arts and Sciences.

Authors:  Scott Barry Kaufman; Lena C Quilty; Rachael G Grazioplene; Jacob B Hirsh; Jeremy R Gray; Jordan B Peterson; Colin G DeYoung
Journal:  J Pers       Date:  2015-01-28

8.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Mary P Cosimano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2014-09-11       Impact factor: 4.153

9.  Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach.

Authors:  Lars H Pinborg; Karen H Adams; Claus Svarer; Søren Holm; Steen G Hasselbalch; Steven Haugbøl; Jacob Madsen; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2003-08       Impact factor: 6.200

10.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Authors:  Stephen Ross; Anthony Bossis; Jeffrey Guss; Gabrielle Agin-Liebes; Tara Malone; Barry Cohen; Sarah E Mennenga; Alexander Belser; Krystallia Kalliontzi; James Babb; Zhe Su; Patricia Corby; Brian L Schmidt
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

View more
  5 in total

1.  Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain.

Authors:  Vasko Kramer; Agnete Dyssegaard; Jonathan Flores; Cristian Soza-Ried; Frank Rösch; Gitte Moos Knudsen; Horacio Amaral; Matthias M Herth
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-12       Impact factor: 9.236

2.  Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study.

Authors:  Dea Siggaard Stenbaek; Sara Kristiansen; Daniel Burmester; Martin Korsbak Madsen; Vibe Gedsoe Frokjaer; Gitte Moos Knudsen; Patrick MacDonald Fisher
Journal:  Hum Brain Mapp       Date:  2019-01-11       Impact factor: 5.038

Review 3.  Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.

Authors:  Paul Cumming; Milan Scheidegger; Dario Dornbierer; Mikael Palner; Boris B Quednow; Chantal Martin-Soelch
Journal:  Molecules       Date:  2021-04-22       Impact factor: 4.411

Review 4.  Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.

Authors:  John R Kelly; Claire M Gillan; Jack Prenderville; Clare Kelly; Andrew Harkin; Gerard Clarke; Veronica O'Keane
Journal:  Front Psychiatry       Date:  2021-12-17       Impact factor: 4.157

5.  Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels.

Authors:  Marie Spies; Arafat Nasser; Brice Ozenne; Peter S Jensen; Gitte M Knudsen; Patrick M Fisher
Journal:  Hum Brain Mapp       Date:  2020-07-22       Impact factor: 5.038

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.